Financial Projections
Bottom-up model for growth, burn, runway, and funding strategy.
Key Metrics
Current baseline assumptions:
Recommended Raise
£350.0K
SEIS intended
Avg Monthly Burn
£22.0K
Peak: £24.6K
M12 MRR
£5.3K
ARPA: £68/mo
M12 Paying Clinics
78.7
152 onboarded total
The Ask
Derived bottom-up from the 12-month cost plan and conservative revenue ramp. Not goal-seeked from a target raise.
£250K
Runs out ~month 11
£350.0K
RecommendedFull 12-month plan + 3-month buffer. 15 months total runway.
£500K
22 months runway. Substantial buffer for iteration.
12-Mo Costs
£302.2K
12-Mo Revenue
£38.2K
Peak Burn/mo
£24.6K
M12 MRR
£5.3K
Initial Raise
£350.0K
Funds 12-month plan (fixed)
Follow-On Raise
£250K
At M15 (with-raise scenario)
Organic EBITDA+
M25
First cash-positive month
With-Raise EBITDA+
M25
First cash-positive month
Organic Growth
No further raise — initial capital only
EBITDA+ Month
M25
M36 Cash
£324.3K
M36 MRR
£88.0K
M36 ARPA
£118/mo
Paying clinics at M36: 745.2
Lowest cash point: -£39.9K at M24
Y3 annual revenue: £797.1K
With Follow-On Raise
+£250K at Month 15, 2 additional reps
EBITDA+ Month
M25
M36 Cash
£712.0K
M36 MRR
£138.7K
M36 ARPA
£127/mo
Paying clinics at M36: 1,090.1
Lowest cash point: £45.6K at M14
Y3 annual revenue: £1.2M
Growth Assumptions
What-If Explorer
Drag sliders to stress-test assumptions. P&L, charts and metrics update live. The Ask and funding requirement remain fixed on the Base Case baseline.
Onboarding
Adoption Rates
ARPA Components
3-Year Growth Assumptions
Both scenarios
- ARPA grows 18–20% per year through upsell (£49 → £99 website tiers, more leads per clinic)
- Adoption rates increase 10–12pp per year per service as product proves ROI
- Monthly churn drops 1.5pp per year (stickier product, better onboarding)
- Rep productivity increases +2 clinics/rep/month per year (experience, referral networks)
- CMA final orders (Sep 2026) drive significant inbound clinic interest from Y2
- Salaries increase 4% annually
Organic scenario
- No additional capital or hires beyond Y1 plan
- Aggressive cost discipline: freelancer costs halved by Y3 (absorbed by team)
- Ad spend reduced — focus on organic/SEO channels that are already working
- 8 inbound clinics/mo in Y2, 18 in Y3 (CMA + brand compounding)
With follow-on raise
- +£250K at M15 (SEIS/EIS)
- 2 additional account reps hired at M16 and M18 (5 total)
- Sustained marketing investment accelerates inbound
- 12 inbound clinics/mo in Y2, 25 in Y3 (paid + organic compounding)
Cash Position
Cash Position — 3-Year Horizon
Comparing organic growth vs. with a £250K follow-on raise at M15.
Annual P&L Comparison
| OrganicY1 | OrganicY2 | OrganicY3 | + RaiseY1 | + RaiseY2 | + RaiseY3 | |
|---|---|---|---|---|---|---|
| Revenue | £38,211 | £212,569 | £797,146 | £38,211 | £258,423 | £1,213,465 |
| Total Costs | -£302,206 | -£338,454 | -£432,997 | -£302,206 | -£447,484 | -£648,449 |
| EBITDA | -£263,992 | -£125,880 | £364,148 | -£263,992 | -£189,056 | £565,011 |
| Paying Clinics (end) | 78.7 | 289.4 | 745.2 | 78.7 | 380.8 | 1,090.1 |
| ARPA (end) | £68/mo | £89/mo | £118/mo | £68/mo | £92/mo | £127/mo |
Year 2 Monthly P&L — Organic
| Line Item | M13 | M14 | M15 | M16 | M17 | M18 | M19 | M20 | M21 | M22 | M23 | M24 | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| REVENUE | |||||||||||||
| Managed Websites | £4,766 | £5,600 | £6,412 | £7,205 | £7,977 | £8,731 | £9,465 | £10,181 | £10,880 | £11,560 | £12,224 | £12,871 | £107,872 |
| Pay-Per-Lead | £3,736 | £4,012 | £4,714 | £5,398 | £6,065 | £6,716 | £7,350 | £7,968 | £8,571 | £9,159 | £9,732 | £10,291 | £83,712 |
| Payment Processing | £942 | £1,020 | £1,095 | £1,287 | £1,474 | £1,656 | £1,833 | £2,007 | £2,175 | £2,340 | £2,500 | £2,657 | £20,986 |
| Total Revenue | £9,444 | £10,632 | £12,222 | £13,890 | £15,516 | £17,102 | £18,648 | £20,156 | £21,626 | £23,059 | £24,456 | £25,818 | £212,569 |
| Cost of Revenue | -£1,475 | -£1,647 | -£1,841 | -£2,115 | -£2,382 | -£2,643 | -£2,897 | -£3,145 | -£3,386 | -£3,621 | -£3,851 | -£4,075 | -£33,078 |
| Gross Profit | £7,969 | £8,985 | £10,381 | £11,775 | £13,134 | £14,459 | £15,752 | £17,011 | £18,240 | £19,437 | £20,605 | £21,744 | £179,492 |
| OPERATING EXPENSES | |||||||||||||
| Salaries & Benefits | -£17,073 | -£17,073 | -£17,073 | -£17,073 | -£17,073 | -£17,073 | -£17,073 | -£17,073 | -£17,073 | -£17,073 | -£17,073 | -£17,073 | -£204,876 |
| Freelancers & Agencies | -£4,225 | -£4,225 | -£4,225 | -£4,225 | -£4,225 | -£4,225 | -£4,225 | -£4,225 | -£4,225 | -£4,225 | -£4,225 | -£4,225 | -£50,700 |
| Ad Spend (Media) | -£1,750 | -£1,750 | -£1,750 | -£1,750 | -£1,750 | -£1,750 | -£1,750 | -£1,750 | -£1,750 | -£1,750 | -£1,750 | -£1,750 | -£21,000 |
| Platform & Overhead | -£2,400 | -£2,400 | -£2,400 | -£2,400 | -£2,400 | -£2,400 | -£2,400 | -£2,400 | -£2,400 | -£2,400 | -£2,400 | -£2,400 | -£28,800 |
| Total OpEx | -£25,448 | -£25,448 | -£25,448 | -£25,448 | -£25,448 | -£25,448 | -£25,448 | -£25,448 | -£25,448 | -£25,448 | -£25,448 | -£25,448 | -£305,376 |
| EBITDA | -£17,478 | -£16,463 | -£15,067 | -£13,673 | -£12,314 | -£10,988 | -£9,696 | -£8,436 | -£7,208 | -£6,010 | -£4,843 | -£3,704 | -£125,880 |
| Cumulative EBITDA | -£281,471 | -£297,934 | -£313,001 | -£326,674 | -£338,988 | -£349,976 | -£359,672 | -£368,109 | -£375,317 | -£381,327 | -£386,170 | -£389,874 | -£389,874 |
| METRICS | |||||||||||||
| New Clinics | 26 | 26 | 26 | 26 | 26 | 26 | 26 | 26 | 26 | 26 | 26 | 26 | 312 |
| Active Clinics | 152.8 | 175 | 196.6 | 217.7 | 238.3 | 258.3 | 277.8 | 296.9 | 315.5 | 333.6 | 351.3 | 368.5 | 368.5 |
| Paying Clinics | 106.6 | 122.8 | 141 | 159.2 | 176.9 | 194.2 | 211.1 | 227.6 | 243.6 | 259.2 | 274.5 | 289.4 | 289.4 |
| ARPA | £89 | £87 | £87 | £87 | £88 | £88 | £88 | £89 | £89 | £89 | £89 | £89 | £89 |
Year 2 Monthly P&L — With Follow-On Raise
| Line Item | M13 | M14 | M15 | M16 | M17 | M18 | M19 | M20 | M21 | M22 | M23 | M24 | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| REVENUE | |||||||||||||
| Managed Websites | £4,996 | £6,023 | £7,025 | £8,002 | £9,031 | £10,073 | £11,281 | £12,497 | £13,797 | £15,066 | £16,302 | £17,508 | £131,601 |
| Pay-Per-Lead | £3,951 | £4,244 | £5,116 | £5,967 | £6,797 | £7,671 | £8,556 | £9,581 | £10,614 | £11,719 | £12,797 | £13,847 | £100,860 |
| Payment Processing | £1,045 | £1,131 | £1,215 | £1,465 | £1,709 | £1,946 | £2,197 | £2,450 | £2,744 | £3,040 | £3,356 | £3,664 | £25,962 |
| Total Revenue | £9,992 | £11,398 | £13,357 | £15,434 | £17,536 | £19,690 | £22,033 | £24,528 | £27,156 | £29,825 | £32,455 | £35,019 | £258,423 |
| Cost of Revenue | -£1,589 | -£1,792 | -£2,025 | -£2,373 | -£2,722 | -£3,070 | -£3,449 | -£3,838 | -£4,268 | -£4,700 | -£5,140 | -£5,570 | -£40,536 |
| Gross Profit | £8,403 | £9,606 | £11,332 | £13,061 | £14,815 | £16,620 | £18,584 | £20,690 | £22,888 | £25,125 | £27,315 | £29,449 | £217,888 |
| OPERATING EXPENSES | |||||||||||||
| Salaries & Benefits | -£17,073 | -£17,073 | -£17,073 | -£20,590 | -£20,590 | -£24,107 | -£24,107 | -£24,107 | -£24,107 | -£24,107 | -£24,107 | -£24,107 | -£261,148 |
| Freelancers & Agencies | -£6,500 | -£6,500 | -£6,500 | -£6,500 | -£6,500 | -£6,500 | -£6,500 | -£6,500 | -£6,500 | -£6,500 | -£6,500 | -£6,500 | -£78,000 |
| Ad Spend (Media) | -£3,250 | -£3,250 | -£3,250 | -£3,250 | -£3,250 | -£3,250 | -£3,250 | -£3,250 | -£3,250 | -£3,250 | -£3,250 | -£3,250 | -£39,000 |
| Platform & Overhead | -£2,400 | -£2,400 | -£2,400 | -£2,400 | -£2,400 | -£2,400 | -£2,400 | -£2,400 | -£2,400 | -£2,400 | -£2,400 | -£2,400 | -£28,800 |
| Total OpEx | -£29,223 | -£29,223 | -£29,223 | -£32,740 | -£32,740 | -£36,257 | -£36,257 | -£36,257 | -£36,257 | -£36,257 | -£36,257 | -£36,257 | -£406,948 |
| EBITDA | -£20,820 | -£19,616 | -£17,891 | -£19,679 | -£17,925 | -£19,637 | -£17,672 | -£15,567 | -£13,369 | -£11,131 | -£8,942 | -£6,807 | -£189,056 |
| Cumulative EBITDA | -£284,813 | -£304,429 | -£322,320 | -£341,999 | -£359,924 | -£379,561 | -£397,233 | -£412,800 | -£426,169 | -£437,301 | -£446,242 | -£453,050 | -£453,050 |
| METRICS | |||||||||||||
| New Clinics | 30 | 30 | 30 | 32 | 33 | 38 | 39 | 42 | 42 | 42 | 42 | 42 | 442 |
| Active Clinics | 156.8 | 182.9 | 208.3 | 235.1 | 262.2 | 293.7 | 325.3 | 359.2 | 392.2 | 424.4 | 455.8 | 486.4 | 486.4 |
| Paying Clinics | 108.7 | 127.9 | 149.6 | 171.4 | 194 | 217 | 242.9 | 269.7 | 298.1 | 326.3 | 353.9 | 380.8 | 380.8 |
| ARPA | £92 | £89 | £89 | £90 | £90 | £91 | £91 | £91 | £91 | £91 | £92 | £92 | £92 |
Exit Scenarios
Four exit pathways — three based on operating performance, one on asset value alone. Each is backed by recent transaction evidence.
Asset acquisition (domains, data & technology)
Any of the above • Media groups • SEO roll-ups • Vet tech platforms
These assets exist today — they are not contingent on future revenue. An acquirer buys the platform not for its P&L but for the cost and time they would need to replicate what has already been built. This floor only grows as more domains age, more data is collected, and more clinics are onboarded.
330 owned domains
Aged, indexed .com domains with established authority across every major UK town, plus .co.uk redirects. Programmatic SEO infrastructure already ranking for thousands of local vet queries.
£200–500K
Aged .com domains with traffic sell for £500–2K each; portfolio premium for coverage + infrastructure
Pricing dataset
The UK's most comprehensive vet pricing database — thousands of procedures across thousands of clinics, with historical depth. No equivalent exists publicly.
£150–400K
Proprietary datasets in regulated industries command significant premiums; cost-to-assemble would exceed £500K+
Technology platform
Clinic onboarding pipeline, automated price extraction engine, hosted website builder, lead attribution system, and CMA compliance tooling.
£100–250K
Replacement development cost; 18+ months of engineering at current build rate
Clinic relationships
Direct relationships with hundreds of practices. Claimed profiles, connected Google accounts, active lead dashboards — each one a switching cost.
£50–200K
Customer acquisition cost of £200–500 per clinic × number of active relationships
Why this matters for investors
This asset floor exists today, providing downside protection from day one — independent of revenue traction. Even in a scenario where the revenue model underperforms, the domains, data, technology, and clinic relationships have been assembled at a cost that far exceeds their purchase price during the seed stage. Any acquirer would pay a meaningful sum to avoid the 2–3 year build time and the domain-aging timeline that cannot be accelerated.
Estimated combined asset floor today: £500K–£1.35M
Private equity & vet practice roll-ups
IVC Evidensia · VetPartners · CVS Group · Linnaeus · Medivet
PE-backed consolidators acquire 300+ practices per year and need deal-flow intelligence, competitive pricing data, and consumer demand routing. Vet Monopoly's pricing dataset, clinic relationships, and lead engine would be expensive and slow to replicate.
Precedent transactions
- IVC Evidensia: Valued at €12.3B (2021, EQT IX + Silver Lake + Nestlé). Revenue tripled since 2017 merger.
- VetPartners: BC Partners acquired for £720M (2018) → valued at £3B by 2022. Revenue CAGR 25.6%, EBITDA CAGR 21.1%.
- CVS Group: Listed, ~9% UK market share. FY26 acquisitions clearing 12.3% post-tax returns.
PE roll-ups pay 8–15× EBITDA for strategic data/tech assets. VetPartners achieved 4.2× value increase in 4 years.
Pet insurance companies
ManyPets · Agria · Santévet · Pinnacle Pet · Petplan
The UK pet insurance market is worth £2B+ in GWP with £1.2B+ annual claims. Insurers price policies using actuarial estimates with limited real-time procedure data. A platform tracking actual vet charges across thousands of procedures and clinics is transformative for underwriting, claims validation, fraud detection, and panel vet steering.
Precedent transactions
- ManyPets: Raised $477M through Series D, £1B+ valuation. £241M GWP. First profit in 2025.
- Santévet Group: Majority stake in Tedaisy (£35M GWP) in 2025, then acquired pet-tech app Perro — appetite for data + distribution.
- Pinnacle Pet Group: Acquired C&F Pet UK (Pet Protect, VioVet) — consolidating insurance + pet commerce.
Insurtech acquisitions valued at 5–15× revenue. Data assets command premium due to underwriting leverage.
Price comparison & marketplace platforms
Moneysupermarket · Compare the Market · RVU (Zoopla/Confused.com) · GoCompare
Comparison platforms expand into adjacent verticals — RVU now owns Confused.com and uSwitch alongside Zoopla. Vet services is a natural next vertical: high search intent, fragmented suppliers, price opacity. A platform with 330 domains, deep SEO infrastructure, and an existing clinic dataset is cheaper to acquire than build.
Precedent transactions
- Confused.com + Penguin Portals: Acquired by RVU for £508M (2021).
- GoCompare: Acquired by Future plc for £594M (2020) — ~4.2× revenue on £142M turnover.
- uSwitch: Acquired by Zoopla for £160M (2015).
Private comparison acquisitions at 10–19× EBITDA. Listed comps: Rightmove 21.8×, Auto Trader 9.4×, Moneysupermarket 6.8× EV/EBITDA.
Illustrative Y3 exit value range
Revenue-based multiples applied to baseline Y3 annual revenue. The asset floor above (£500K–£1.35M) exists today and only grows — it is not dependent on hitting these revenue targets. All figures are directional — actual valuation depends on growth rate, margins, strategic premium, and market conditions at exit.
| Multiple | Basis | Organic | With raise |
|---|---|---|---|
| 5× revenue | Conservative (early-stage SaaS) | £4.0M | £6.1M |
| 10× revenue | Comparison site M&A range | £8.0M | £12.1M |
| 15× revenue | Strategic premium / high-growth | £12.0M | £18.2M |
Revenue multiples used as proxy for operating exits. EBITDA multiples would be higher (10–22×) but require mature margin assumptions.
Methodology: Cohort-based revenue model with per-service adoption rates, activation delays, and monthly churn applied to each onboarding cohort independently. Employer NI at 15% above £5,000 threshold (2025/26 UK rates). Auto-enrolment pension at 3%.
Revenue caution: Revenue generation always takes longer than expected. The conservative scenario uses longer activation delays, lower adoption rates, and higher churn to reflect this reality.
Account rep benchmark: £35K base salary. UK vet pharma sales reps earn £28–33K base + company car + OTE (job board data 2025). £35K premium reflects no company car or meaningful Y1 commission. Target profile: 3–5 years vet industry experience with existing clinic relationships.
3-year growth drivers: CMA regulations (effective Sep 2026) create regulatory tailwind for price transparency — driving inbound clinic interest. Product improvements, rep experience, and brand recognition compound to increase adoption rates and reduce churn over time.